Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Feb 22, 2024 1:36pm
35 Views
Post# 35893779

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Let's be more balanced and positive

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Let's be more balanced and positive
Tencents wrote: To add
the ceo also said this gets into 40 m plant investissement alluding to his conclusion that this was way out of czo capabilities - presumably having sub contract manufacture in mind ( Natex or somebody else )



That was before the merger. The upfront payment from Strongbridge alone for AEZS's diagnostic was $40 million adjusted for inflation and capital from AEZS is to be directed at CZO's near-term revenue opportunities. . 

<< Previous
Bullboard Posts
Next >>